Navigation Links
Infinata's BioPharm Insight Global Editor Kim Ha to Moderate Panel at 3rd Annual U.S.-China Conference on Strategies for Mining Profits from Pharma Opportunities in China
Date:4/15/2013

Norwood, MA (PRWEB) April 15, 2013

BioPharm Insight Global Editor Kimberly Ha will moderate a panel discussion on “Emerging Licensing Opportunities” at the 3rd Annual U.S.-China Conference on Strategies for Mining Profits from Pharma Opportunities in China, May 20-21 in Boston, Mass.

BioPharm Insight offers the global biopharmaceutical community a unique combination of business intelligence, market analytics, key industry contacts, and award-winning independent investigative journalism.

The panel of China and Asia market experts will discuss strategies to maximize the value of drug candidates starting in the pre-clinical development stage. Presenters will explore strategies small to mid-size drug developers should take to position themselves for out-licensing, and discuss emerging opportunities for licensing in China/Asia. Panelists will cover alternative investment approaches and new ways to structure the deals. They also will share case studies and best practices to align goals with deal opportunities, navigate negotiation challenges, and establish clear protocols to manage relationships and create lucrative partnerships.

Panelists include:

  •     Wei Zhang, Ph.D., Head, Corporate Development, Good Start Genetics Inc.
  •     Vincent Liu, Chief Representative New York, Shanghai Fosun Pharmaceutical Group
  •     Les Funtleyder, MPH, Healthcare Strategist, Polliwog Investment Advisors
  •     Mark Yang, PhD, MBA, Managing Director and Chairman, WT Global Capital

Kimberly Ha is an award-winning biopharmaceutical industry journalist and editor. She launched BioPharm Insight's editorial team in 2007. Kimberly began her career as a financial journalist in Hong Kong specializing in healthcare M&A, and previously was the lead sector specialist at Mergermarket, a division of the Financial Times Group. She is a sought-after panelist and moderator at major healthcare investor conferences and events. Kimberly is a member of the Galien Foundation Advisory Board. She has received fellowships from organizations including the National Press Foundation, the UN Foundation for Global Vaccines, and the Association of Health Care Journalists. Kimberly earned her Bachelor’s in Psychology from New York University.

About BioPharm Insight
BioPharm Insight is the definitive guide to the global biopharma community. BioPharm Insight provides subscribers with an information edge by combining the most comprehensive real-time database of companies, drugs, contacts, M&A and licensing deals, forecasts and clinical trial data with proprietary forward-looking intelligence uncovered by an independent team of investigative journalists months or even years before it breaks in mainstream media. To learn more, visit http://www.biopharminsight.com. Follow BioPharm Insight on LinkedIn and Twitter.

About Infinata, Inc.
Infinata provides personalized technology solutions to turn information into insight. Services include a comprehensive BioPharm Solutions Suite, unique Wealth Prospecting tools and innovative Custom Data Services. Infinata is a part of Mergermarket, a Financial Times Group company and a division of Pearson plc. To learn more, visit http://www.infinata.com.

Read the full story at http://www.prweb.com/releases/2013/4/prweb10624121.htm.


'/>"/>
Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related biology technology :

1. Infinata's BioPharm Clinical™ to Present Session on Improving Investigator Selection at CHI’s Summit for Clinical Operations (SCOPE) on February 6 in Miami, FL
2. Infinata's BioPharm Insight Journalist Awarded Fellowship by Association of Health Care Journalists
3. Keryx Biopharmaceuticals, Inc. Announces Upcoming Poster Presentations of Zerenex™ (Ferric Citrate) at the Upcoming American Society of Nephrology Kidney Week 2011 Annual Meeting
4. PDL BioPharma Announces Adjusted Conversion Rates for Its Convertible Notes
5. CeNeRx BioPharma Completes $4.85 Million Financing
6. PDL BioPharma Completes Regular Quarterly Dividend Payment
7. PAREXEL Introduces Executive Briefing Series on Proven Practices to Assist Emerging and Mid-size Biopharma in Achieving Better Outcomes
8. Inspiration Biopharmaceuticals Moves Corporate Headquarters to Cambridge, Massachusetts
9. Keryx Biopharmaceuticals to Present at JP Morgans 30th Annual Healthcare Conference
10. HealthCare Institute of New Jersey Releases 2011 Biopharmaceutical and Medical Technology Economic Impact Data
11. Sigma-Aldrich to Acquire BioReliance; Extending Its Reach into Biopharmaceutical Testing and Services
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/23/2017)... , ... March 23, 2017 , ... ... material that exhibits both viscous and elastic characteristics when deformed, which is identical ... exhibits properties to gently absorb compressive forces and return to its natural state ...
(Date:3/23/2017)... , March 23, 2017  SeraCare ... to global in vitro diagnostics manufacturers and ... the industry,s first multiplexed Inherited Cancer ... testing by next-generation sequencing (NGS). The Seraseq™ ... developed with input from industry experts to ...
(Date:3/23/2017)... , March 23, 2017 Kineta, ... development of novel therapies in immuno-oncology, today announced ... lead" small molecule compounds that activate interferon response ... pathways and demonstrate immune-mediated tumor regression in a ... the study who demonstrated complete tumor regression to ...
(Date:3/23/2017)... 2017 In today,s pre-market research, ... the Biotech industry: Sangamo Therapeutics Inc. (NASDAQ: SGMO), Eyegate ... SYN), and Regulus Therapeutics Inc. (NASDAQ: RGLS ... Suisse upgraded its rating on Pharmaceuticals/Biotechnology to "Overweight" from "Market Weight." Learn ... at: ...
Breaking Biology Technology:
(Date:3/7/2017)... , March 7, 2017 Brandwatch , the ... by The Prince,s Trust to uncover insights to support ... The Trust. The UK,s leading youth charity will be ... campaign results and get a better understanding of the topics and ... ...
(Date:3/2/2017)... YORK , March 2, 2017 Summary ... better understand Perrigo and its partnering interests and activities since ... ... Partnering Deals and Alliance since 2010 report provides an in-depth ... leading life sciences companies. On demand company reports ...
(Date:3/2/2017)... , March 2, 2017 Australian stem cell ... (ASX: CYP), has signed an agreement with the Monash ... Monash Biomedicine Discovery Institute and Department of Pharmacology at ... a further preclinical study to support the use of ... asthma.  Asthma is a chronic, long ...
Breaking Biology News(10 mins):